UBX Unity Biotechnology

UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference

UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 11:20 AM ET.

The webcast of the presentation will be accessible and through the “Investors and Media” section of our website, , under “Events & Presentations.”

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at or follow us on and .



Media Contact
Evoke Canale
Katherine Smith
 

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
EN
15/02/2023

Underlying

UBXUnity Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Unity Biotechnology

 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE...

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population  UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST

May 5, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for D...

May 1, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology Announces Publication in NEJM Evidence Highlightin...

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, “Safety and Efficacy of Senolytic UBX1325 in D...

April 23, 2025 1 EN
 PRESS RELEASE
Free
UBX Unity Biotechno...

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results...

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements ...

April 22, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
PBF PBF Energy Inc... ... (+19)

InsiderInsights.com Daily Ratings Report: April 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CDXS CODEXIS
WGO WINNEBAGO INDUSTRIES INC.
UBX UNITY BIOTECHNOLOGY
FGBI FIRST GUARANTY BANCSHARES
PCB PACIFIC CITY FINANCIAL CORP
APA APA CORPORATION
NUVB NUVATION BIO INC (A)
FTCI FTC SOLAR
BTMD INC.
TEAF HAYMAKER ACQUISITION CORP III
BTM ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
STSFF BITCOIN DEPOT INC
ECF SMARTSTOP SELF STORAGE REIT
INC.
ELLSWORTH FUND LTD
04/04/25 April 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch